C4 Therapeutics, Inc.
CCCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.00 | 0.04 | -0.05 |
| FCF Yield | -19.63% | -12.06% | -29.37% | -7.05% |
| EV / EBITDA | -4.76 | -3.09 | -4.40 | -8.09 |
| Quality | ||||
| ROIC | -14.60% | -11.04% | -10.25% | -12.20% |
| Gross Margin | 0.00% | 67.75% | 100.00% | 65.89% |
| Cash Conversion Ratio | 0.97 | 0.46 | 1.26 | 0.52 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.95% | 28.78% | 13.51% | 4.60% |
| Free Cash Flow Growth | -158.27% | 63.22% | -85.66% | 25.67% |
| Safety | ||||
| Net Debt / EBITDA | -0.08 | 0.55 | -0.46 | -0.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -65.65 | 69.29 | -13.75 |